OptiNose - OPTN Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year target prices for OptiNose's shares. Their OPTN share price forecasts range from $4.00 to $5.00. On average, they expect the company's share price to reach $4.67 in the next year. This suggests a possible upside of 182.8% from the stock's current price.
View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts.

OptiNose's stock was trading at $1.85 at the start of the year. Since then, OPTN stock has decreased by 10.8% and is now trading at $1.65.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our OPTN earnings forecast.

OptiNose, Inc. (NASDAQ:OPTN) issued its earnings results on Monday, November, 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. The business had revenue of $21.83 million for the quarter, compared to the consensus estimate of $23.90 million. During the same period in the previous year, the company posted ($0.43) earnings per share.

OptiNose updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $17.49 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by many different institutional and retail investors. Top institutional shareholders include MVM Partners LLC (17.49%), Kingdon Capital Management L.L.C. (3.77%), Armistice Capital LLC (2.39%), Nantahala Capital Management LLC (1.74%), Rice Hall James & Associates LLC (0.97%) and Stonepine Capital Management LLC (0.61%). Insiders that own company stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends.

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPTN stock can currently be purchased for approximately $1.65.

OptiNose (NASDAQ:OPTN) has a market capitalization of $184.49 million and generates $76.28 million in revenue each year. The company earns $-74,830,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

The company employs 189 workers across the globe.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The official website for the company is www.optinose.com. The company can be reached via phone at (267) 364-3500 or via email at investors@optinose.com.